Back to Search
Start Over
Mechanisms of acquired afatinib resistance in HER2-positive breast cancer cells
- Source :
- Journal of Clinical Oncology. 33:620-620
- Publication Year :
- 2015
- Publisher :
- American Society of Clinical Oncology (ASCO), 2015.
-
Abstract
- 620 Background: Afatinib is a potent irreversible ErbB family tyrosine kinase inhibitor. We have previously shown that afatinib has anti-proliferative activity in a panel of 8 HER2 positive breast ...
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........3d905a319f983abeb998a0b8d78260d0
- Full Text :
- https://doi.org/10.1200/jco.2015.33.15_suppl.620